Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers

7 Oct 2021

Abstract excerpt

Cancer treatment is constantly evolving from a one-size-fits-all towards bespoke approaches for each patient. In certain solid cancers, including breast and lung, tumor genome profiling has been incorporated into therapeutic decision-making. For chronic phase chronic myeloid leukemia (CML), while tyrosine kinase inhibitor therapy is the standard treatment, current clinical scoring systems cannot accurately...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34615339
DOI: 10.3324/haematol.2021.279317

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkersPMID 34615339Read ↗

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemiaSemantic proximity Read ↗

Expression profiling of leukemia patients: Key lessons and future directionsSemantic proximity Read ↗

Network-based clustering unveils interconnected landscapes of genomic and clinical features across myeloid malignanciesSemantic proximity Read ↗

Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia.Semantic proximity Read ↗

Omics approaches: Role in acute myeloid leukemia biomarker discovery and therapySemantic proximity Read ↗

Classification and risk assessment in AML: integrating cytogenetics and molecular profilingSemantic proximity Read ↗

Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profilingSemantic proximity Read ↗

How will genomic testing impact a clinician's choice for managing chronic myeloid leukemia?Semantic proximity Read ↗

Investigation of molecular heterogeneity and new prognostic biomarkers in chronic myeloid leukaemiaSemantic proximity Read ↗

Phenocopies in acute lymphoblastic leukemia: Redefining leukemia subtypes in the transcriptomic era.Semantic proximity Read ↗

Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia.Semantic proximity Read ↗

Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.